Author: O’Connell, Grant C.; Treadway, Madison B.; Petrone, Ashley B.; Tennant, Connie S.; Lucke-Wold, Noelle; Chantler, Paul D.; Barr, Taura L.
Title: Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption Document date: 2017_4_26
ID: 1ey6ie95_2
Snippet: The median time from symptom onset to blood draw across all discovery cohort subjects was 7.4 hours. In terms of clinical and demographics characteristics, patients presenting with severe HARM at 24 follow up were significantly older and displayed a higher prevalence of dyslipidemia relative to patients presenting with lower levels of HARM (Table 1) . Furthermore, a higher proportion of patients presenting with severe HARM received thrombolytic i.....
Document: The median time from symptom onset to blood draw across all discovery cohort subjects was 7.4 hours. In terms of clinical and demographics characteristics, patients presenting with severe HARM at 24 follow up were significantly older and displayed a higher prevalence of dyslipidemia relative to patients presenting with lower levels of HARM (Table 1) . Furthermore, a higher proportion of patients presenting with severe HARM received thrombolytic intervention via recombinant tissue plasminogen activator (rtPA) than those presenting with lower levels of HARM, however this difference was not statistically significant.
Search related documents:
Co phrase search for related documents- median time and recombinant tissue rtPA plasminogen activator: 1
- median time and rtPA plasminogen activator: 1
- median time and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- median time and symptom onset median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- plasminogen activator and recombinant tissue rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- plasminogen activator and rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- plasminogen activator and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- plasminogen activator and symptom onset median time: 1, 2, 3
- plasminogen activator and thrombolytic intervention: 1
- plasminogen activator and tissue rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- recombinant tissue rtPA plasminogen activator and rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- recombinant tissue rtPA plasminogen activator and symptom onset: 1, 2, 3
- recombinant tissue rtPA plasminogen activator and symptom onset median time: 1
- recombinant tissue rtPA plasminogen activator and tissue rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- rtPA plasminogen activator and symptom onset: 1, 2, 3, 4
- rtPA plasminogen activator and symptom onset median time: 1
- rtPA plasminogen activator and tissue rtPA plasminogen activator: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- symptom onset and tissue rtPA plasminogen activator: 1, 2, 3, 4
- symptom onset median time and tissue rtPA plasminogen activator: 1
Co phrase search for related documents, hyperlinks ordered by date